Development Pipeline

Today, our research efforts are dedicated to advancing a diverse pipeline of innovative therapies for solid tumors and blood-related cancers.
Learn about our development programs by selecting an agent below or click to explore our interactive pipeline.

Brentuximab vedotin

an antibody–drug conjugate directed to CD30 being investigated in certain lymphomas and solid tumors

  • Phase 2
  • Phase 3

View Program